Loading clinical trials...

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy

NCT01282073•Kyungpook National University Hospital

View on ClinicalTrials.gov

Summary

Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.

Detailed Description

Idiopathic membranous nephropathy is most common cause of glomerulonephritis in adults. Persistent high grade proteinuria or progressively decrease of renal function is a risk factor for end stage renal disease in idiopathic membranous nephropathy. It has been reported that cyclosporin in patients with idiopathic membranous nephropathy decreases proteinuria and improve renal function. Mycophenolate mofetil is a recently developed immunosuppressive agent with fewer side effect than cyclosporin. In this study patients with high risk group of progressive idiopathic membranous nephropathy will be treated with mycophenolate mofetil and low dose prednisone. The outcome will be compared to controls treated with cyclosporin and low dose prednisone.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients with idiopathic membranous nephropathy
•2. The duration of disease is less than twelve months
•3. Patients with persistent proteinuria more than 8 grams per day
•4. Patients who provided informed consent
•5. The cases that satisfy more than three of following items even if proteinuria is less than 8 grams per day:
•* eGFR \< 60 ml/min/1.73m2
•* Hypertension (BP above 140/90mmHg or BP above 120/80 in patients taking anti-hypertensive agents)
•* 24 hours urine protein or spot urine protein/creatinine ratio \> 5.0 g/day
•* Serum albumin (g/dL) \< 3.0
•* Selectivity index \> 0.2

Exclusion Criteria

•1. Severe digestive organ disease
•2. Allergy history to clinical trial medication and acute or chronic allergy for 4 weeks recently.
•3. Clinical history of treatment with other immunosuppressive medication
•4. Probability of pregnancy, breast feeding woman
•5. Uncontrolled hypertension (more than 160/100mmHg)
•6. Uncontrolled systemic disease
•7. Drug addiction or alcoholics within 6 months
•8. eGFR is less than 30ml/min at screening
•9. Abnormal liver function test (more than 3 times above compared with normal value)
•10. Absolute neutrophil count \<1,500/mm3 or leukocyte \<2,500/mm3 or platelets \<100,000/mm3
+2 more criteria

Locations (9)

Dong-A University Medical Center

Busan, South Korea

Inje University Haeundae Paik Hospital

Busan, South Korea

Kyungpook National University Hospital

Daegu, South Korea

Daegu Fatima Hospital

Daegu, South Korea

Yeungnam University Medical Center

Daegu, South Korea

Seoul National University Hospital

Seoul, South Korea

Yonsei University Hospital

Seoul, South Korea

Boramae Medical Center

Seoul, South Korea

Ulsan University Hospital

Ulsan, South Korea

Key Dates

Start Date

March 1, 2011

Primary Completion Date

May 1, 2016

Completion Date

May 1, 2016

Last Updated

August 27, 2025

Enrollment

ACTUAL participants

Conditions

Glomerulonephritis, Membranous

Interventions

Mycophenolate mofetil, low dose steroid

DRUG

Cyclosporin, low dose steroid

DRUG

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

NCT04145440

Glomerulonephritis, MembranousantiPLA2R Positive

View study

UNKNOWNPHASE3

Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy

NCT03018535

Glomerulonephritis, Membranous

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions